Skip to main content
Erschienen in: Obesity Surgery 11/2020

02.07.2020 | Original Contributions

Safety and Effectiveness of an Intragastric Balloon as an Adjunct to Weight Reduction in a Post-Marketing Clinical Setting

verfasst von: Rachel L. Moore, Laura Eaton, Julie Ellner

Erschienen in: Obesity Surgery | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

Background and Objectives

Obesity and its related comorbidities are associated with serious health risks. This trial evaluated the safety and effectiveness of the ORBERA® Intragastric Balloon System (IGB) as an adjunct to lifestyle intervention in a post-marketing clinical setting.

Methods and Materials

In this multicenter study, 258 adults with a body mass index of 30–40 kg/m2 were treated with the IGB as an adjunct to weight reduction and followed for up to 12 months. The primary objective was to demonstrate in a post-marketing clinical setting that the incidence of device and procedure-related serious adverse events (SAEs) after 26 weeks of IGB treatment is no greater than 15%.

Results

The incidence of device and procedure-related SAEs was 8.9% with a 1-sided upper limit confidence interval of 12.4%, compared with the 9.6% overall SAE rate seen in the US pivotal study; therefore, the primary safety endpoint was met. The key secondary effectiveness endpoint was also met with a mean maximum %TBWL of 12.5 being achieved at the time of IGB removal (26 weeks).

Conclusions

The post-marketing safety and effectiveness profile of the IGB are consistent with what was observed in the US pivotal study. No new risks were identified.

Clinical trial registration: Clinical Trials.​gov NCT02828657

Literatur
1.
Zurück zum Zitat NIH. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - The evidence report. Obes Res 1998;6(Suppl 2)(51S–209S). NIH. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - The evidence report. Obes Res 1998;6(Suppl 2)(51S–209S).
2.
Zurück zum Zitat Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015–20162017 Oct. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015–20162017 Oct.
3.
Zurück zum Zitat Gottig S, Daskalakis M, Weiner S, et al. Analysis of safety and efficacy of intragastric balloon in extremely obese patients. Obes Surg. Jun 2009;19(6):677–83.PubMedCrossRef Gottig S, Daskalakis M, Weiner S, et al. Analysis of safety and efficacy of intragastric balloon in extremely obese patients. Obes Surg. Jun 2009;19(6):677–83.PubMedCrossRef
4.
Zurück zum Zitat Courcoulas A, Abu Dayyeh BK, Eaton L, et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. International journal of obesity (2005). Mar. 2017;41(3):427–33. Courcoulas A, Abu Dayyeh BK, Eaton L, et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. International journal of obesity (2005). Mar. 2017;41(3):427–33.
5.
Zurück zum Zitat Abeid M, Kaddah T, Zaitoun N, et al. Efficacy and safety of intragastric balloon placements in 1600 cases, an experience from the Middle East. Obes Surg. 2019;29(7):2087–91.PubMedCrossRef Abeid M, Kaddah T, Zaitoun N, et al. Efficacy and safety of intragastric balloon placements in 1600 cases, an experience from the Middle East. Obes Surg. 2019;29(7):2087–91.PubMedCrossRef
6.
Zurück zum Zitat Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg. Jun-Jul 2005;15(6):864–70.PubMedCrossRef Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg. Jun-Jul 2005;15(6):864–70.PubMedCrossRef
7.
Zurück zum Zitat Alfredo G, Roberta M, Massimiliano C, et al. Long-term multiple intragastric balloon treatment--a new strategy to treat morbid obese patients refusing surgery: prospective 6-year follow-up study. Surg Obes Relat Dis. 2014;10(2):307–11.PubMedCrossRef Alfredo G, Roberta M, Massimiliano C, et al. Long-term multiple intragastric balloon treatment--a new strategy to treat morbid obese patients refusing surgery: prospective 6-year follow-up study. Surg Obes Relat Dis. 2014;10(2):307–11.PubMedCrossRef
8.
Zurück zum Zitat Genco A, Bruni T, Doldi S, et al. BioEnterics intragastric balloon: the Italian experience with 2,515 patients. Obes Surg. 2005;15(8):1161–4.PubMedCrossRef Genco A, Bruni T, Doldi S, et al. BioEnterics intragastric balloon: the Italian experience with 2,515 patients. Obes Surg. 2005;15(8):1161–4.PubMedCrossRef
9.
Zurück zum Zitat Genco A, Cipriano M, Bacci V, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients. Obes Surg. 2010;20(11):1496–500.PubMedCrossRef Genco A, Cipriano M, Bacci V, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients. Obes Surg. 2010;20(11):1496–500.PubMedCrossRef
10.
Zurück zum Zitat Genco A, Lopez-Nava G, Wahlen C, et al. Multi-centre European experience with intragastric balloon in overweight populations: 13 years of experience. Obes Surg 2013;23(4):515–521. Genco A, Lopez-Nava G, Wahlen C, et al. Multi-centre European experience with intragastric balloon in overweight populations: 13 years of experience. Obes Surg 2013;23(4):515–521.
11.
Zurück zum Zitat Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg. 2009;19(8):1084–8.PubMedCrossRef Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg. 2009;19(8):1084–8.PubMedCrossRef
12.
Zurück zum Zitat Genco A, Cipriano M, Materia A, et al. Laparoscopic sleeve gastrectomy versus intragastric balloon: a case-control study. Surg Endosc. 2009;23(8):1849–53.PubMedCrossRef Genco A, Cipriano M, Materia A, et al. Laparoscopic sleeve gastrectomy versus intragastric balloon: a case-control study. Surg Endosc. 2009;23(8):1849–53.PubMedCrossRef
13.
Zurück zum Zitat Mui WL, Ng EK, Tsung BY, et al. Impact on obesity-related illnesses and quality of life following intragastric balloon. Obes Surg. 2010;20(8):1128–32.PubMedCrossRef Mui WL, Ng EK, Tsung BY, et al. Impact on obesity-related illnesses and quality of life following intragastric balloon. Obes Surg. 2010;20(8):1128–32.PubMedCrossRef
14.
Zurück zum Zitat Kotzampassi K, Grosomanidis V, Papakostas P, et al. 500 intragastric balloons: what happens 5 years thereafter? Obes Surg. Jun 2012;22(6):896–903.PubMedCrossRef Kotzampassi K, Grosomanidis V, Papakostas P, et al. 500 intragastric balloons: what happens 5 years thereafter? Obes Surg. Jun 2012;22(6):896–903.PubMedCrossRef
15.
Zurück zum Zitat Kotzampassi K, Shrewsbury AD, Papakostas P, Penna S, Tsaousi GG, Grosomanidis V. Looking into the profile of those who succeed in losing weight with an intragastric balloon. J Laparoendoscopic Adv Surg Tech. Part A 2014;24(5):295–301. Kotzampassi K, Shrewsbury AD, Papakostas P, Penna S, Tsaousi GG, Grosomanidis V. Looking into the profile of those who succeed in losing weight with an intragastric balloon. J Laparoendoscopic Adv Surg Tech. Part A 2014;24(5):295–301.
16.
Zurück zum Zitat Farina MG, Baratta R, Nigro A, et al. Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obes Surg. Apr 2012;22(4):565–71.PubMedCrossRef Farina MG, Baratta R, Nigro A, et al. Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obes Surg. Apr 2012;22(4):565–71.PubMedCrossRef
17.
Zurück zum Zitat Fuller NR, Pearson S, Lau NS, et al. An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study. Obesity (Silver Spring). Aug 2013;21(8):1561–70.CrossRef Fuller NR, Pearson S, Lau NS, et al. An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study. Obesity (Silver Spring). Aug 2013;21(8):1561–70.CrossRef
18.
Zurück zum Zitat Al-Sabah S, Al-Ghareeb F, Ali DA, et al. Efficacy of intragastric balloon for the management of obesity: experience from Kuwait. Surg Endosc. 2016;30(2):424–9.PubMedCrossRef Al-Sabah S, Al-Ghareeb F, Ali DA, et al. Efficacy of intragastric balloon for the management of obesity: experience from Kuwait. Surg Endosc. 2016;30(2):424–9.PubMedCrossRef
19.
Zurück zum Zitat da Silva J, Proenca L, Rodrigues A, et al. Intragastric balloon for obesity treatment: safety, tolerance, and efficacy. GE Port J Gastroenterol. 2018;25(5):236–42.CrossRef da Silva J, Proenca L, Rodrigues A, et al. Intragastric balloon for obesity treatment: safety, tolerance, and efficacy. GE Port J Gastroenterol. 2018;25(5):236–42.CrossRef
20.
Zurück zum Zitat Forlano R, Ippolito AM, Iacobellis A, et al. Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients. Gastrointest Endosc. 2010;71(6):927–33.PubMedCrossRef Forlano R, Ippolito AM, Iacobellis A, et al. Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients. Gastrointest Endosc. 2010;71(6):927–33.PubMedCrossRef
21.
Zurück zum Zitat Lopez-Nava G, Rubio MA, Prados S, et al. BioEnterics® intragastric balloon (BIB®). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg 2011;21(1):5–9. Lopez-Nava G, Rubio MA, Prados S, et al. BioEnterics® intragastric balloon (BIB®). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg 2011;21(1):5–9.
22.
Zurück zum Zitat Štimac D, Majanović SK, Turk T, et al. Intragastric balloon treatment for obesity: results of a large single-center prospective study. Obes Surg. 2011;21(5):551–5.PubMedCrossRef Štimac D, Majanović SK, Turk T, et al. Intragastric balloon treatment for obesity: results of a large single-center prospective study. Obes Surg. 2011;21(5):551–5.PubMedCrossRef
23.
Zurück zum Zitat Chan AO, Chow WS, Lam KF, et al. The effect of intragastric balloon placement on weight loss and type 2 diabetes control. Aliment Pharmacol Ther. 2008;28(1):162–4. author reply 164-165PubMedCrossRef Chan AO, Chow WS, Lam KF, et al. The effect of intragastric balloon placement on weight loss and type 2 diabetes control. Aliment Pharmacol Ther. 2008;28(1):162–4. author reply 164-165PubMedCrossRef
24.
Zurück zum Zitat Mafort TT, Madeira E, Madeira M, et al. Six-month intragastric balloon treatment for obesity improves lung function, body composition, and metabolic syndrome. Obes Surg. 2014;24(2):232–40.PubMedCrossRef Mafort TT, Madeira E, Madeira M, et al. Six-month intragastric balloon treatment for obesity improves lung function, body composition, and metabolic syndrome. Obes Surg. 2014;24(2):232–40.PubMedCrossRef
25.
Zurück zum Zitat Guedes M, Fittipaldi-Fernandez R, Diestel C, et al. Impact of intragastric balloon treatment on adipokines, cytokines, and metabolic profile in obese individuals. Obes Surg. 2019;29(8):2600–8.PubMedCrossRef Guedes M, Fittipaldi-Fernandez R, Diestel C, et al. Impact of intragastric balloon treatment on adipokines, cytokines, and metabolic profile in obese individuals. Obes Surg. 2019;29(8):2600–8.PubMedCrossRef
26.
Zurück zum Zitat Koc F, Kayaoglu H, Celik A, et al. Effect of weight loss induced by intragastric balloon therapy on cardiac function in morbid obese individuals: a pilot study. Med Princ Pract. 2015;24(5):432–5.PubMedPubMedCentralCrossRef Koc F, Kayaoglu H, Celik A, et al. Effect of weight loss induced by intragastric balloon therapy on cardiac function in morbid obese individuals: a pilot study. Med Princ Pract. 2015;24(5):432–5.PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Reimao S, da Silve M, Nunes G, et al. Improvement of body composition and quality of life following intragastric balloon. Obes Surg. 2018;28(6):1806–8.PubMedCrossRef Reimao S, da Silve M, Nunes G, et al. Improvement of body composition and quality of life following intragastric balloon. Obes Surg. 2018;28(6):1806–8.PubMedCrossRef
29.
Zurück zum Zitat Dumonceau J. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg. 2008 Dec;18(12):1611–7.PubMedCrossRef Dumonceau J. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg. 2008 Dec;18(12):1611–7.PubMedCrossRef
30.
Zurück zum Zitat Gomez V, Woodman G, Abu Dayyeh BK. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: results of a prospective study. Obesity (Silver Spring). 2016;24(9):1849–53.CrossRef Gomez V, Woodman G, Abu Dayyeh BK. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: results of a prospective study. Obesity (Silver Spring). 2016;24(9):1849–53.CrossRef
Metadaten
Titel
Safety and Effectiveness of an Intragastric Balloon as an Adjunct to Weight Reduction in a Post-Marketing Clinical Setting
verfasst von
Rachel L. Moore
Laura Eaton
Julie Ellner
Publikationsdatum
02.07.2020
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 11/2020
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-020-04798-5

Weitere Artikel der Ausgabe 11/2020

Obesity Surgery 11/2020 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.